Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Journal article
Fuggle, Nicholas, Al-Daghri, Nasser, Bock, Olivier, Branco, Jaime, Bruyere, Olivier, Casado, Enrique, Cavalier, Etienne, Cortet, Bernard, de Wit, Maarten, Giusti, Andrea, Halbout, Phillippe, Harvey, Nicholas, Hiligsmann, Mickaël, Kaufman, Jean‑Marc, Kurth, Andreas, Maggi, Stefania, Matijevic, Radmila, Minisola, Salvatore, Palacios, Santiago, ... Cooper, Cyrus. (2022). Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clinical and Experimental Research. 34(11), pp. 2625-2634. https://doi.org/10.1007/s40520-022-02272-z
Authors | Fuggle, Nicholas, Al-Daghri, Nasser, Bock, Olivier, Branco, Jaime, Bruyere, Olivier, Casado, Enrique, Cavalier, Etienne, Cortet, Bernard, de Wit, Maarten, Giusti, Andrea, Halbout, Phillippe, Harvey, Nicholas, Hiligsmann, Mickaël, Kaufman, Jean‑Marc, Kurth, Andreas, Maggi, Stefania, Matijevic, Radmila, Minisola, Salvatore, Palacios, Santiago, Radermecker, Régis, Thomasius, Friederike, Tuzun, Sansin, Veronese, Nicola, Kanis, John Anthony, Reginster, Jean-Yves, Rizzoli, Rene and Cooper, Cyrus |
---|---|
Abstract | Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk–benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes. |
Keywords | Osteoporosis; Bisphosphonates; Fragility fracture; Therapy; Risedronate; Alendronate |
Year | 01 Jan 2022 |
Journal | Aging Clinical and Experimental Research |
Journal citation | 34 (11), pp. 2625-2634 |
Publisher | Springer Nature Switzerland AG |
ISSN | 1594-0667 |
Digital Object Identifier (DOI) | https://doi.org/10.1007/s40520-022-02272-z |
Web address (URL) | https://link.springer.com/article/10.1007/s40520-022-02272-z |
Open access | Open access |
Research or scholarly | Research |
Page range | 2625-2634 |
Publisher's version | License File Access Level Open |
Output status | Published |
Publication dates | |
Online | 04 Oct 2022 |
Publication process dates | |
Accepted | 03 Oct 2022 |
Deposited | 08 Sep 2023 |
Additional information | © The Author(s) 2022. |
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/ licenses/by/4.0/. | |
Place of publication | Switzerland |
https://acuresearchbank.acu.edu.au/item/8z9qv/novel-formulations-of-oral-bisphosphonates-in-the-treatment-of-osteoporosis
Download files
Publisher's version
Kanis_2022_Novel_formulations_of_oral_bisphosphonates_in.pdf | |
License: CC BY 4.0 | |
File access level: Open |
3
total views1
total downloads3
views this month1
downloads this month